EP Patent

EP4630061A1 — Lipid nanoparticles comprising elevated neutral lipid and a targeting moiety for targeted delivery of nucleic acid

Assigned to Nanovation Therapeutics Inc · Expires 2025-10-15 · 1y expired

What this patent protects

Provided herein is a lipid nanoparticle encapsulating nucleic acid and having at least 30 mol% neutral lipid, a sterol or derivative thereof and a targeting moiety anchored in a lipid layer thereof via a lipophilic moiety. Further provided are methods of using the lipid nanoparti…

USPTO Abstract

Provided herein is a lipid nanoparticle encapsulating nucleic acid and having at least 30 mol% neutral lipid, a sterol or derivative thereof and a targeting moiety anchored in a lipid layer thereof via a lipophilic moiety. Further provided are methods of using the lipid nanoparticles for targeted delivery in vivo. Such lipid nanoparticle may exhibit significantly improved delivery and targeting to extrahepatic tissues and/or organs.

Drugs covered by this patent

Patent Metadata

Patent number
EP4630061A1
Jurisdiction
EP
Classification
Expires
2025-10-15
Drug substance claim
No
Drug product claim
No
Assignee
Nanovation Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.